Medtronic Inc. CEO William Hawkins tells MassDevice that he's encouraged by changes to the 510(k) program detailed today by the Food & Drug Administration, but adds that there's more work to be done to eliminate "uncertainty."

Medtronic Inc. (NYSE:MDT) CEO William "Bill" Hawkins reacted positively to changes the Food & Drug Administration announced today for its 510(k) program, calling them a "positive sign" that regulators are open to working more collaboratively with industry but denying that the medical device industry won a round in the fight against stricter regulation.
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...